Please Subscribe to get a daily link to Pat's blog via email


Your privacy is important to us. We will never spam you and keep your personal data secure.

Monthly Archives: May 2010

31 05, 2010

New IMF Publication Provides Details Of New Multiple Myeloma Novel Therapy Studies & Applications

Tags: , |0 Comments

The International Myeloma Foundation produces a quarterly publication called "Citings- Novel Therapies in Multiple Myeloma."  This research review features the most up-to-date information on research advances and new therapies for the treatment for multiple myeloma.  Since the publication covers many of the new myeloma drugs I write about regularly, I thought some of you might

30 05, 2010

Mayo Clinic’s Dr. Shaji Kumar Continues Investigation Into The Biggest Single Question Facing Multple Myeloma Patients Today: Should You Transplant Now Or Later?

Tags: , , , |2 Comments

I saved the last edition of the International Myeloma Foundation's (IMF) Myeloma Today on my "get to as soon as possible" pile near my computer.  The full color newsletter, done very professionally in color, on thick, glossy stock, was folded open to an article about Dr. Shaji Kumar's ongoing study comparing continued initial therapy and

29 05, 2010

Back To Basics: What Is Induction Therapy? Why Is It Important For Treating Multiple Myeloma?

Tags: , , , , , |0 Comments

Recent e-mails have reminded me just how many newly diagnosed patients and/or caregivers log-on to this site each and every day. Keeping this in mind, I thought it was time to bring back my "Back to Basics" series, designed to help bring our new readers up to speed.One question: What is induction therapy? According to

28 05, 2010

Notes From Today’s 11 AM Tele-News Conference About New Multiple Myeloma Advances Being Introduced At ASCO – Featuring Dr. Brian Durie

Tags: , , , , , , , , |4 Comments

I listened to a pre-ASCO teleconference today with the International Myeloma Foundation's (IMF) Dr. Brian Durie. The preview was titled: NEW PARADIGMS OF TREATMENT- FIRST LOOK AT LONG-TERM DATA FROM 2 MULTI-NATIONAL TRIALS EVALUATING MYELOMA MAINTENANCE THERAPY AFTER TRANSPLANT. I have been covering a number of the studies Dr. Durie was discussing. The big news

27 05, 2010

Say It Isn’t So In 2010—African American Multiple Myeloma Patients Face Therapy Discrimination

Tags: , , , , |0 Comments

The Medical College of Wisconsin published an important press release this week.  The title:  African-Americans and women are less likely to undergo bone marrow transplantation.This single paragraph, found near the end of the release, sums up the disturbing results:The researchers' analysis revealed that HCT is more frequently used to treat leukemia, lymphoma, and multiple myeloma in

25 05, 2010

Clarification About New Oral Proteasome Inhibitor–MLN9708 From Millennium

Tags: , , , , , |6 Comments

Sunday, I ran a story about Millennium Pharmaceutical's upcoming research presentations at ASCO. At the end of the article, I commented about the lack of attention being paid to Millennium's development of an "oral Velcade," a new drug, MLN9708.For years, the myeloma community has heard rumors Millennium was close to unveiling such a drug.  Now, practically

24 05, 2010

ASCO News About Bisphosphonates

Tags: , , |0 Comments

There has been a long standing debate among the myeloma community concerning bisphosphonates.  Many myeloma docs now believe Zometa and Aredia provide anti-myeloma benefits, in addition to helping bones recover.  I received the following e-mail Friday from Larry, following release of pre-ASCO research data.  Larry represents a group of multiple myeloma patients who take this research very,

23 05, 2010


Tags: , , , , , , |1 Comment

I learned yesterday VELCADE is being highlighted in five presentations at the newly established, exclusive Trials in Progress session. This session will highlight a number of different abstracts. “Data being presented at this year’s ASCO further demonstrate the effectiveness of VELCADE as a backbone of therapy in a range of multiple myeloma patient populations and

22 05, 2010

Here Is A Link To Mayo Clinic’s Consensus Multiple Myeloma Treatment Strategy For Newly Diagnosed Patients: mSMART

Tags: , , , |0 Comments

Mayo Clinic has come up with a name and treatment map for newly diagnosed multiple myeloma patients called mSMART. mSMART (Mayo Stratification for Myeloma And Risk-adapted Therapy) is a consensus opinion by 26 of Mayo Clinic's myeloma specialists, which takes into account genetically determined risk status and the various treatment strategies currently available.Go to mSMART

21 05, 2010

Onyx Pharmaceuticals Announces Carfilzomib Data Presentations at 46th American Society of Clinical Oncology Annual Meeting

Tags: , , , , |2 Comments

Here are parts of a press release Onyx, makers of the new drug, carfilzomib, released last night at 6:00 PM:Emeryville, CA – May 20, 2010 – Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the presentation of several studies evaluating carfilzomib, a selective, next-generation proteasome inhibitor, at the 46th American Society of Clinical Oncology (ASCO) Annual

20 05, 2010

I Will Be Reporting Live From This Year’s ASCO Meeting In Chicago, June 4th – 8th

Tags: , , , |2 Comments

I am excited to announce I will be reporting from this year's annual American Society of Clinical Oncology (ASCO) meetings Chicago June 4th - 8th.  This is America's largest gathering of clinical oncologists and researchers.  I will be writing a daily column for The Myeloma Beacon from the event.  I will also be blogging live here, and

20 05, 2010

New Growth Factor Drug For Multiple Myeloma May Also Help Leukemia Patients

Tags: , , , |0 Comments

Here is a link to an abstract with an update about advances in stem cell mobilization:  Update on clinical experience with AMD3100, an SDF-1/CXCL12-CXCR4 inhibitor, in mobilization of hematopoietic stem and progenitor cells.Interpreting this is beyond my pay grade!  Best I can tell, AMD3100 is a new stem cell mobilizer, with possible benefits as a

19 05, 2010

Link To Mayo Clinic Podcast About Multiple Myeloma

Tags: |0 Comments

In the following video, Rafael Fonseca, M.D., Director of the Cancer Center at Mayo Clinic in Arizona, provides an overview of the condition Multiple Myeloma along with basic treatment options:  Mayo Clinic podcast about multiple myeloma.  This short, five minute presentation is worth a look.  Feel good and keep smiling!  Pat

18 05, 2010

Reflections From A Caregiver: "In this cancer community of survivors, how do we promote the power of positive thinking and not leave behind those who’s treatments are failing to impact the disease?"

Tags: , , , , , , , |0 Comments

I have been e-mailing back and forth with a caregiver named Kate.  She originally contacted me about an article I wrote last week, An Ambiguous Multiple Myeloma Maintenance Therapy Study Is Still Worth A Look.  As I often do, I was commenting on one of the numerous research studies I often read.  Here is the

15 05, 2010

New Multiple Myeloma Drug, CGEN-928 Official Press Release

Tags: , |0 Comments

A few days ago I teased you with an initial announcement about a new multiple myeloma drug, CGEN-928.  I promised I would follow-up.  Here is the complete release, provided by Business Wire:Compugen Ltd. announced today the discovery and initial experimental validation of CGEN-928 as a drug target for the treatment of multiple myeloma. In recently

14 05, 2010

Inspirational Multiple Myeloma Patient Profile: Blogger Nick van Dyk

Tags: , , , , , , |5 Comments

As part of the continuing series about inspirational multiple myeloma patients, I would like to introduce you to Nick van Dyk from Los Angeles.  Over the past year or so, Nick and I have become close friends. Last year, Nick wrote a three part essay, Living WITHOUT Multiple Myeloma, about his experiences with multiple myeloma and

12 05, 2010

An Ambiguous Multiple Myeloma Maintenance Therapy Study Is Still Worth A Look

Tags: , , |1 Comment

Here is a research study abstract I found on, posted May 11, 2010:Maintenance with thalidomide improved PFS, not OS in multiple myeloma.Maintenance therapy with thalidomide extended PFS for patients with multiple myeloma, but such therapy did not result in a similar benefit for OS, according to results from a European study.From August 2001 to

11 05, 2010

It’s Always Great To Hear From My Readers!

Tags: |2 Comments

I receive a number of e-mails each and every day from readers.  They ask questions, share their stories and sometimes give me support and advice about medical and emotional issues in my life.  I love hearing from you!  It makes my day every time one of you leaves a comment on one of the blogs